Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Average Rating of "Moderate Buy" by Analysts

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $1.83.

Several brokerages have issued reports on ADAP. Guggenheim lowered their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. StockNews.com began coverage on shares of Adaptimmune Therapeutics in a research report on Thursday, May 8th. They issued a "buy" rating for the company. Scotiabank lowered their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research report on Friday, March 21st. Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Finally, Wells Fargo & Company lowered their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st.

Adaptimmune Therapeutics Trading Down 4.8%

ADAP traded down $0.01 on Friday, reaching $0.28. 16,069,796 shares of the company's stock were exchanged, compared to its average volume of 1,811,759. The company's 50 day moving average is $0.30 and its 200-day moving average is $0.51. The company has a market cap of $72.28 million, a price-to-earnings ratio of -1.29 and a beta of 2.86. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.48. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. Equities analysts predict that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in ADAP. Invesco Ltd. lifted its stake in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after buying an additional 28,526 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after buying an additional 58,787 shares during the last quarter. Two Sigma Investments LP lifted its stake in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after buying an additional 19,146 shares during the last quarter. Virtu Financial LLC lifted its stake in Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after buying an additional 21,688 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after buying an additional 94,623 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.